GlassScriptPhysician profile
Steven Rodriguez
NPI 1841752920
$3,713.16
in general payments reported to CMS, 2019-2025
12 companies · $3,713 in 2025
The $3,713 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,300 · Food and Beverage: $1,281 · Travel and Lodging: $81.00 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,300.00 |
| Food and Beverage | $1,281.21 |
| Travel and Lodging | $81.00 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $3,195.50 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $148.53 | 2025 | Compliance Endokit |
| Janssen Biotech, INC. | $94.31 | 2025 | Tremfya |
| Abbvie INC. | $66.65 | 2025 | |
| Exact Sciences Corporation | $44.90 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $38.08 | 2025 | Wegovy |
| Vivus LLC | $29.36 | 2025 | Qsymia |
| Braintree Laboratories, INC. | $21.95 | 2025 | Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2025 | Entyvio |
| Pfizer INC. | $19.00 | 2025 | |
| Celltrion USA INC. | $18.82 | 2025 | Vegzelma |
| Capsovision, INC. | $15.19 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.